MedPath

CTEPH DIAGNOSIS Europe - MRI

Phase 3
Conditions
Pulmonary Hypertension
Registration Number
NCT02791282
Lead Sponsor
Hannover Medical School
Brief Summary

Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH where positive findings are verified with catheter pulmonary angiography (CPA), or computed tomography pulmonary angiography (CTPA)

Detailed Description

CHANGE-MRI is a prospective, multicentre, comparative phase III diagnostic study. The study aims to show via an in-place validation that MRI can replace VQ-SPECT as a screening test for chronic pulmonary embolism in the diagnostic algorithm for CTEPH. The diagnostic gold standard is catheter pulmonary angiography (CPA) or computed tomography pulmonary angiography (CTPA) with correction from the clinical outcome after 6-12 months.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1080
Inclusion Criteria
  • Transthoracic echocardiography indicates pulmonary hypertension
  • Patients with clinical suspicion for CTEPH, scheduled for SPECT
  • Provided informed consent for the study
  • Age >18y
Exclusion Criteria
  • Patient unable to undergo MRI (e.g. due to claustrophobia, cardiac pacemaker, hypersensitivity to MR i.v. contrast imaging agents)
  • Women who are pregnant or breast feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The proportion of patients with positive MRI in the group of patients with negative VQ-SPECT who are negative in the gold standard6 months
The proportion of patients with positive MRI in the group of patients who have a positive VQ-SPECT diagnosis for chronic pulmonary embolism and who are positive in the gold standard6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hannover Medical School

🇩🇪

Hannover, Lower Saxony, Germany

© Copyright 2025. All Rights Reserved by MedPath